- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Tongue Carcinoma.
Displaying page 1 of 1.
EudraCT Number: 2019-003022-24 | Sponsor Protocol Number: N19IFC | Start Date*: 2019-10-15 | |||||||||||||||||||||
Sponsor Name:NKI-AVL | |||||||||||||||||||||||
Full Title: INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer) | |||||||||||||||||||||||
Medical condition: Penile cancer and tongue cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003977-10 | Sponsor Protocol Number: HNBE-03-02 | Start Date*: 2004-11-12 |
Sponsor Name:Genetronics Biomedical Corporation | ||
Full Title: A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Pri... | ||
Medical condition: Patients with locally recurrent or second primary SCC of the base tongue, posterior lateral pharyngeal wall, hypopharynx and larynx. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006091-38 | Sponsor Protocol Number: DeLOSII | Start Date*: 2007-05-31 | ||||||||||||||||
Sponsor Name:Universität Leipzig | ||||||||||||||||||
Full Title: Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngek... | ||||||||||||||||||
Medical condition: by laryngectomy operable carcinoma of the larynx and the hypopharynx | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013402-14 | Sponsor Protocol Number: INTECEPTOR-TRIAL | Start Date*: 2009-09-17 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | |||||||||||||
Full Title: INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin | |||||||||||||
Medical condition: locally advanced squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002244-16 | Sponsor Protocol Number: NRG-HN002 | Start Date*: 2016-09-12 | |||||||||||
Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland | |||||||||||||
Full Title: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | |||||||||||||
Medical condition: Locoregionally advanced oropharyngeal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-005015-13 | Sponsor Protocol Number: C0947 | Start Date*: 2018-05-18 | |||||||||||
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
Full Title: NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer | |||||||||||||
Medical condition: Locally advanced squamous cell carcinoma of the oral cavity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006981-27 | Sponsor Protocol Number: C14007 | Start Date*: 2011-01-13 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or G... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Phase I portion of the study - Advanced nonhematologic malignancies. Phase II portion of the study - Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), adenocarcinoma of the esop... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004627-33 | Sponsor Protocol Number: GSN000400 | Start Date*: 2022-02-03 | |||||||||||
Sponsor Name:Genkyotex Suisse SA | |||||||||||||
Full Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxi... | |||||||||||||
Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003702-41 | Sponsor Protocol Number: IDR-OM-02 | Start Date*: 2018-07-03 |
Sponsor Name:Soligenix UK Limited | ||
Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for... | ||
Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003554-23 | Sponsor Protocol Number: NL68976.041.19 | Start Date*: 2021-12-03 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: Sentinel lymph node detection in early-stage ORal Cavity squamous cell carcinoma using Magnetic Resonance (MR) lymphogrAphy | |||||||||||||||||||||||
Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with early-stage oral cavity squamous cell carcinoma and a clinically negative neck (T1-3, N0, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002745-38 | Sponsor Protocol Number: GTI-4419-202 | Start Date*: 2020-01-16 | |||||||||||
Sponsor Name:Galera Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with Chemorad... | |||||||||||||
Medical condition: Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002323-25 | Sponsor Protocol Number: AA1720 | Start Date*: 2017-09-22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Center for cancer immune therapy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Adoptive cell therapy across cancer diagnoses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003389-26 | Sponsor Protocol Number: RG14-093 | Start Date*: 2015-01-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer | |||||||||||||
Medical condition: Oropharyngeal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004914-32 | Sponsor Protocol Number: NL71558.041.19 | Start Date*: 2020-03-12 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET-CT | |||||||||||||||||||||||
Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with early-stage oral squamous cell carcinoma and a clinically negative neck (T1-3N0M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Temporarily Halted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002466-39 | Sponsor Protocol Number: CFTSp032 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:The Christie NHS Foundation Trust | |||||||||||||
Full Title: A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemot... | |||||||||||||
Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000999-11 | Sponsor Protocol Number: MNPR-301-001 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Monopar Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2b/3, multicenter, randomized, double-blind, placebocontrolled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induce... | |||||||||||||
Medical condition: Chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014870-16 | Sponsor Protocol Number: BA2009-28-01 | Start Date*: 2009-12-10 |
Sponsor Name:BioAlliance Pharma | ||
Full Title: A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad® 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once da... | ||
Medical condition: Prevention and treatment of chemoradion therapy-induced oral mucositis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) DE (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000197-30 | Sponsor Protocol Number: UoL001289 | Start Date*: 2018-07-13 |
Sponsor Name:The University of Liverpool | ||
Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia | ||
Medical condition: High Risk Oral Epithelial Dysplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001256-22 | Sponsor Protocol Number: GL0817-01 | Start Date*: 2017-01-31 | |||||||||||
Sponsor Name:Gliknik Inc | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients wi... | |||||||||||||
Medical condition: Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
